Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 3/20 | 0.42 |
| ▸ | NR1H4 | Q96RI1 | 3/20 | 0.42 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ESRRG | P62508 | 3/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | ESRRB | O95718 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | PTPRC | P08575 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27474422 | 1.00 | EPHX2 (0.42) | EPHX2NR1H4ADRB2ADRB1ESRRG | |
| SCHEMBL6829407 | 0.89 | NR1H4 (0.54) | EPHX2NR1H4ESRRGRAB9AESRRB | |
| Hydrochloric Acid SCHEMBL6829405 | 0.88 | NR1H4 (0.53) | EPHX2NR1H4ESRRGRAB9AESRRB | |
| SCHEMBL6221022 | 0.84 | EPHX2 (0.43) | EPHX2NR1H4ADRB2ADRB1 | |
| SCHEMBL9430861 | 0.83 | EPHX2 (0.39) | EPHX2NR1H4ESRRGRAB9AKMT2A | |
| SCHEMBL4495372 | 0.81 | EPHX2 (0.48) | EPHX2NR1H4ADRB2ADRB1ESRRG | |
| SCHEMBL5664578 | 0.81 | EPHX2 (0.46) | EPHX2NR1H4MAPTKMT2AMEN1 | |
| SCHEMBL5663152 | 0.80 | MLYCD (0.40) | MAPTKMT2AMEN1PTPRCALDH1A1 | |
| SCHEMBL6016224 | 0.80 | HPGD (0.44) | RAB9ASMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL6016221 | 0.79 | HPGD (0.43) | RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6838453-B2 | Antagonist derivatives of the vitronectin receptor | AVENTIS PHARMA S.A. (FR) | 2005-01-04 | — | — | US | disclosed |
| CN-1177832-C | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | ���ĵ�˹ҩƷ�¹��ɷ�����˾ | 2004-12-01 | — | — | CN | disclosed |
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | AVENTIS PHARMA S.A. (FR) | 2004-11-11 | — | — | US | disclosed |
| US-6747148-B2 | FOR THERPY AND PROPHYLAXIS OF OSTEOPOROSIS, HYPERCALCEMIA, OR OSTEOPENIA, INFLAMMATION, CARDIOVASCULAR DISORDERS, RESTENOSIS, ARTERIOSCLEROSIS, NEPHROPATHIES OR RETINOPATHIES | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2004-06-08 | — | — | US | disclosed |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | PEYMAN ANUSCHIRWAN (DE) | 2002-05-30 | — | — | US | disclosed |
| US-6313119-B1 | VITRONECTIN RECEPTOR ANTAGONISTS | ADVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-11-06 | — | — | US | disclosed |
| CN-1293662-A | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | AIWENTIS DRUG DEUTSCHLAND GMBH (DE) | 2001-05-02 | — | — | CN | disclosed |
| EP-1049677-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | Aventis Pharma Deutschland GmbH (DE) | 2000-11-08 | — | — | EP | disclosed |
| WO-1999037621-A1 | NOVEL SULFONAMIDE DERIVATIVES AS INHIBITORS OF BONE RESORPTION AND AS INHIBITORS OF CELL ADHESION | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 1999-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040225111-A1 | ANTAGONIST DERIVATIVES OF THE VITRONECTIN RECEPTOR | ADGRF1, BDKRB1, ADGRE5 | EPHX2 728/4885NR1H4 1126/4885ADRB2 71/4885 |
| US-20020065271-A1 | Novel sulfonamide derivatives as inhibitors of bone resorption and as inhibitors of cell adhesion | SOST, SELPLG, BST2 | EPHX2 2032/4885NR1H4 1240/4885ADRB2 2060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.